Hostname: page-component-745bb68f8f-lrblm Total loading time: 0 Render date: 2025-01-21T22:05:55.873Z Has data issue: false hasContentIssue false
  • English
  • Français

Detection of Psychotomimetic N,N-Dimethylated Indoleamines in the Urine of Four Schizophrenic Patients

Published online by Cambridge University Press:  29 January 2018

Hiroshi Tanimukai ,
Rowena Ginther ,
Joanne Spaide ,
Joao R. Bueno  and
Harold E. Himwich
Hiroshi Tanimukai
Affiliation:
Thudicum Psychiatric Research Laboratory, Galesburg State Research Hospital, Galesburg, Illinois, 61401
Rowena Ginther
Affiliation:
Thudicum Psychiatric Research Laboratory, Galesburg State Research Hospital, Galesburg, Illinois, 61401
Joanne Spaide
Affiliation:
Thudicum Psychiatric Research Laboratory, Galesburg State Research Hospital, Galesburg, Illinois, 61401
Joao R. Bueno
Affiliation:
Thudicum Psychiatric Research Laboratory, Galesburg State Research Hospital, Galesburg, Illinois, 61401
Harold E. Himwich
Affiliation:
Thudicum Psychiatric Research Laboratory, Galesburg State Research Hospital, Galesburg, Illinois, 61401
Get access Rights & Permissions [Opens in a new window]

Extract

Pollin, Cardon and Kety (18) investigated the effects of large doses of various amino acids in combination with a monoamine oxidase (MAO) inhibitor on the behaviour of schizophrenics. They found that methionine in the presence of such an inhibitor was capable of producing behavioural changes which may ‘represent a biochemically induced acute flare-up of a chronic schizophrenic process on the one hand, or a toxic delirium superimposed upon chronic schizophrenia on the other’. Brune and Himwich (8) confirmed the clinical results of Pollin et al. On the basis of their previous work indicating that tryptamine appeared in increased concentrations in the urine before and during the activation of psychotic symptoms, they suggested that under loading conditions the formation of various N,N-dimethylated indoleamines might be facilitated in the body. The tertiary indoleamines so formed might mediate the psychotic effect of methionine with a MAO inhibitor on schizophrenic patients.

Type
Research Article
Information
The British Journal of Psychiatry , Volume 117 , Issue 539 , October 1970 , pp. 421 - 430
Copyright
Copyright © Royal College of Psychiatrists, 1970 

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

1. Alexander, F., Curtis, G. C., Springe, H., and Crosley, A. P. (1963). ‘L-methionine and L-tryptophan feedings in non-psychotic and schizophrenic patients with and without tranylcypromine.’ J. nerv. merit. Dis., 137, 135–42.Google Scholar
2. Arnold, O. H., and Hofmann, G. (1957). ‘Zur Psychopathologie des Dimethyltryptamine: ein weiterer Beitrag zur Pharmakopsychiatrie: vorläufige Mitteilung.’ Wien Z. Nervenheilk, 13, 438–45.Google Scholar
3. Axelrod, J. (1961). ‘Enzymatic formation of psychotomimetic metabolites from normally occurring compounds.’ Science, 134, 343.Google Scholar
4. Axelrod, J. (1962). ‘The enzymatic N-methylation of serotonin and other amines.’ J. Pharmacol. Exp. Ther., 138, 28–33.Google Scholar
5. Berlet, H. H., Bull, C., Himwich, H. E., Kohl, H., Matsumoto, K., Pscheidt, G. R., Spaide, J., Tourlentes, T. T., and Valverde, J. M. (1964). ‘Endogenous metabolic factor in schizophrenic behavior.’ Science, 144, 311–13.Google ScholarPubMed
6. Berlet, H. H., Matsumoto, K., Pscheidt, G. R., Spaide, J., Bull, C., and Himwich, H. E. (1965). ‘Biochemical correlates of behavior in schizophrenic patients.’ Arch. gen. Psychiat., 13, 521–31.Google Scholar
7. Brune, G. G. (1965). ‘Metabolism of biogenic amines and psychotropic drug effects in schizophrenic patients.’ In Horizons in Neuropsychopharmacology, Progress in Brain Research (eds. Himwich, W. A. and Schadé, J. P.). Vol. 16, pp. 81–96. Amsterdam: Elsevier.Google Scholar
8. Brune, G. G. and Himwich, H. E. (1962). ‘Effects of methionine loading on the behavior of schizophrenic patients.’ J. nerv. ment. Dis., 134, 447–50.Google Scholar
9. Brune, G. G. and Psheidt, G. R. (1961). ‘Correlations between behavior and urinary excretion of indoleamines and catecholamines in schizophrenic patients as affected by drugs.’ Fed. Proc., 20, 889–93.Google Scholar
10. Brune, G. G., Psheidt, G. R. and Himwich, H. E. (1963). ‘Different responses of urinary tryptamine and of total catecholamines during treatment with reserpine and isocarboxazid in schizophrenic patients.’ Int. J. Neuropharmacol., 2, 17–23.Google Scholar
11. Capella, P., and Horning, E. C. (1966). ‘Separation and identification of derivatives of biologic amines by gas-liquid chromatography.’ Anal. Chem., 38, 316–21.Google Scholar
12. Downing, D. F. (1964). ‘Psychotomimetic compounds.’ In Psychopharmacological Agents (ed. Gordon, M.). Vol. 1, pp. 555–618. New York: Academic Press.Google Scholar
13. Fabing, H. D., and Hawkins, J. R. (1956). ‘Intra-venous bufotenine injection in the human being.’ Science, 123, 886–7.Google Scholar
14. Gessner, P. K., Khairallah, P. A., McIsaac, W. M., and Page, I. H. (1960). ‘The relationship between the metabolic fate and pharmacological actions of serotonin, bufotenine and psilocybin.’ J. Pharmacol. exp. Ther. 130, 126–33.Google Scholar
15. Gessner, P. K. and Page, I. H. (1962). ‘Behavioral effects of 5-methoxy-N: N-dimethyltryptamine, other tryptamines, and LSD.’ Amer. J. Physiol., 203, 167–72.Google Scholar
16. Park, L. C., Baldessarini, R. J., and Kety, S. S. (1965). ‘Methionine effects on chronic schizophrenics.’ Arch. gen. Psychiat., 12, 346–351.Google Scholar
17. Perry, T. L., Shaw, K. N. F., Walker, D., and Redlich, D. (1962). ‘Urinary excretion of amines in normal children.’ Pediatrics, 30, 576–84.Google Scholar
18. Pollin, W., Cardon, P. V., and Kety, S. S. (1961). ‘Effects of amino acid feedings in schizophrenic patients treated with iproniazid.’ Science, 133, 104–5.CrossRefGoogle ScholarPubMed
19. Rosenberg, D. E., Isbell, H., and Miner, E. J. (1963). ‘Comparison of a placebo, N-dimethyltryptamine, and 6-hydroxy-N-dimethyltryptamine in man.’ Psychopharmacologia, 4, 39–42.Google Scholar
20. Spaide, J., Tanimukai, H., Ginther, R., Bueno, J., and Himwich, H. E. (1967). ‘Schizophrenic behavior and urinary tryptophan metabolites associated with cysteine given with and without a monoamine oxidase inhibitor (tranylcypromine).’ Life Sci., 6, 551–60.Google Scholar
21. Springe, H., Parker, C. M., Jameson, D., and Alexander, F. (1963). ‘Urinary indoles in schizophrenic and psychoneurotic patients after administration of tranylcypromine (Parnate) and methionine or tryptophan.’ J. nerv. ment. Dis., 137, 246–51.Google Scholar
22. Szara, S. (1956). ‘Dimethyltryptamine: its metabolism in man; the relation of its psychotic effect to the serotonin metabolism.’ Experientia, 12, 441–2.Google Scholar
23. Tanimukai, H. (1967). ‘Modifications of paper and thin layer chromatographic methods to increase sensitivity for detecting N-methylated indoleamines in urine.’ J. Chromatogr., 30, 155–63.Google Scholar
24. Tanimukai, H., Ginther, R., Spaide, J., and Himwich, H. E. (1967). ‘Psychotomimetic indole compound in the urine of schizophrenics and mentally defective patients.’ Nature, 216, 490–1.Google Scholar
Submit a response

eLetters

No eLetters have been published for this article.